Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China

• Published in: Frontiers in immunology Vol. 13; p. 1080408
• Main Authors: Chen, Yaping, Xiao, Yanhui, Ye, Ying, Jiang, Feng, He, Hanqing, Luo, Linyun, Chen, Haiping, Shi, Lubin, Mu, Qiuyue, Chen, Wei, Guo, Xue, Zhang, Min, Li, Jun, Guan, Qinghu, Chen, Zhiping, Yang, Xiaoming
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 08-12-2022
• Subjects: China; coadministration; Enterovirus A, Human; Hemagglutination Inhibition Tests - methods; HIV Seropositivity; Humans; immunogenicity; Immunology; inactivated enterovirus 71 vaccine; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human - prevention & control; safety; trivalent split-virion inactivated influenza vaccine; Vaccines, Inactivated; Virion; China; trivalent split-virion inactivated influenza vaccine; inactivated enterovirus 71 vaccine; safety; coadministration; immunogenicity
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.1080408

Few data exist on the immunogenicity and safety of an inactivated enterovirus 71 vaccine (EV71 vaccine) coadministered with trivalent split-virion inactivated influenza vaccine (IIV3) in infants.
This trial was a phase 4, randomized, controlled trial. Infants aged 6-11 months were eligible, with no history of hand, foot and mouth disease (HFMD) and no history of EV71 vaccine or any influenza vaccine. Eligible infants were randomly assigned to EV71+IIV3 group, EV71 group or IIV3 group. Blood samples were collected on day 0 and 56.
Between September 2019 and June 2020, 1151 infants met eligibility criteria and 1134 infants were enrolled. 1045 infants were included in the per-protocol population, including 347 in the EV71+IIV3 group, 343 in the EV71 group, and 355 in the IIV3 group. The seroconversion rate (98.56% vs 98.54%; seroconversion rates difference of 0.02% [95% CI: 0.70-0.98]) and GMT (419.05 vs 503.72; GMT ratio of 0.83 [95% CI 0.70 - 0.98]) of EV71 neutralizing antibodies in the EV71+IIV3 group was not inferior to those in the EV71 group. The non-inferiority results for influenza virus antibodies (A/H1N1, A/H3N2 and B) showed that the seroconversion rates and GMTs of the EV71+IIV3 group were non-inferiority to those of the IIV3 group. Systemic and local adverse event rates were similar between groups. None of serious adverse events (SAEs) were related to vaccination.
Coadministration of the EV71 vaccine with IIV3 was safe and did not interfere with immunogenicity. These findings support a viable immunization strategy for infants with the EV71 vaccine coadministered with IIV3 in China. This trial is registered with ClinicalTrials.gov, number NCT04091880.